%	O
%	O
TITLE	O

Association	O
between	O
human	O
papilloma	O
virus	O
/	O
Epstein	O
-	O
Barr	O
virus	O
coinfection	O
and	O
oral	O
carcinogenesis	O
.	O

%	O
%	O
ABSTRACT	O

The	O
recent	O
epidemic	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
associated	O
with	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
has	O
not	O
addressed	O
its	O
association	O
with	O
lymphoid	O
tissue	B-HPV_Sample_Type
in	O
the	O
oropharynx	O
or	O
the	O
potential	O
role	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
/	O
HPV	O
coinfection	O
.	O
The	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
and	O
EBV	O
infection	O
/	O
coinfection	O
and	O
CD21	O
mRNA	O
expression	O
were	O
determined	O
in	O
normal	O
and	O
cancerous	O
tissues	B-HPV_Sample_Type
from	O
the	O
oropharynx	O
using	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	O
p16	O
,	O
and	O
quantitative	B-HPV_Lab_Technique
reverse	I-HPV_Lab_Technique
transcriptase	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
qRT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

The	O
effects	O
of	O
coinfection	O
on	O
tumorigenicity	O
were	O
evaluated	O
using	O
proliferation	O
and	O
invasion	O
assays	O
.	O
Normal	O
oropharynx	O
,	O
tonsil	O
,	O
non	O
-	O
cancer	O
base	O
of	O
tongue	O
(	O
BOT	O
)	O
,	O
and	O
BOT	O
from	O
sleep	O
apnea	O
patients	O
demonstrated	O
EBV	O
positivity	O
ranging	O
from	O
7	O
%	O
to	O
36	O
%	O
depending	O
on	O
the	O
site	O
and	O
methods	O
of	O
detection	O
used	O
(	O
qRT	O
-	O
PCR	O
or	O
ISH	O
)	O
.	O

Among	O
non	O
-	O
malignant	O
BOT	O
samples	B-HPV_Sample_Type
,	I-HPV_Sample_Type
HPV	O
positivity	O
was	O
noted	O
only	O
in	O
20	O
%	O
.	O

The	O
percent	O
of	O
tonsil	O
and	O
BOT	O
cancers	O
positive	O
for	O
HPV	O
(	O
up	O
to	O
63	O
%	O
and	O
80	O
%	O
,	O
respectively	O
)	O
or	O
coinfected	O
with	O
HPV	O
/	O
EBV	O
(	O
up	O
to	O
25	O
%	O
and	O
70	O
%	O
,	O
respectively	O
)	O
were	O
both	O
significantly	O
associated	O
with	O
cancer	O
status	O
.	O

Notably	O
,	O
HPV	O
/	O
EBV	O
coinfection	O
was	O
observed	O
only	O
in	O
malignant	O
tissue	B-HPV_Sample_Type
originating	O
in	O
lymphoid	O
-	O
rich	O
oropharynx	O
sites	O
(	O
tonsil	O
,	O
BOT	O
)	O
.	O

CD21	O
mRNA	O
(	O
the	O
major	O
EBV	O
attachment	O
receptor	O
)	O
was	O
detected	O
in	O
tonsil	O
and	O
BOT	O
epithelium	O
,	O
but	O
not	O
in	O
soft	O
-	O
palate	O
epithelium	O
.	O

Coinfected	O
cell	O
lines	O
showed	O
a	O
significant	O
increase	O
in	O
invasiveness	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
There	O
is	O
a	O
high	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
/	O
EBV	O
infection	O
and	O
coinfection	O
in	O
BOT	O
and	O
tonsil	O
cancers	O
,	O
possibly	O
reflecting	O
their	O
origins	O
in	O
lymphoid	O
-	O
rich	O
tissue	B-HPV_Sample_Type
.	O

In	O
vitro	O
,	O
cells	O
modeling	O
coinfection	O
have	O
an	O
increased	O
invasive	O
potential	O
.	O

%	O
%	O
METHODS	O

Tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type

Tissue	B-HPV_Sample_Type
sections	O
on	O
positively	O
charged	O
slides	O
from	O
archived	O
parafﬁn	O
-	O
embedded	O
blocks	O
were	O
obtained	O
for	O
each	O
of	O
the	O
following	O
categories	O
:	O
(	O
i	O
)	O
tonsil	O
squamous	O
cell	O
carcinomas	O
(	O
SCC	O
)	O
(	O
n	O
=	O
16	O
)	O
;	O
(	O
ii	O
)	O
BOT	O
SCC	O
(	O
n	O
=	O
15	O
)	O
;	O
(	O
iii	O
)	O
soft	O
-	O
palate	O
SCC	O
(	O
n	O
=	O
10	O
)	O
as	O
negative	O
controls	O
;	O
(	O
iv	O
)	O
normal	O
tonsils	O
from	O
patients	O
with	O
obstructive	O
sleep	O
apnea	O
(	O
n	O
=	O
13	O
)	O
;	O
(	O
v	O
)	O
non	O
-	O
cancerous	O
BOT	O
samples	B-HPV_Sample_Type
from	O
random	O
biopsies	B-HPV_Sample_Type
of	O
patients	O
with	O
unknown	O
primaries	O
(	O
n	O
=	O
10	O
)	O
;	O
(	O
vi	O
)	O
normal	O
BOT	O
samples	B-HPV_Sample_Type
from	O
the	O
patients	O
undergoing	O
BOT	O
reduction	O
for	O

obstructive	O
sleep	O
apnea	O
(	O
n	O
=	O
15	O
;	O
obtained	O
from	O
Dr	O
.	O
Eben	O
L	O
.	O

Rosenthal	O
from	O
the	O
University	O
of	O
Alabama	O
at	O
Birmingham	O
)	O
;	O
(	O
vii	O
)	O
soft	O
uvula	O
from	O
patients	O
who	O
underwent	O
uvulopalatopharyngoplasty	O
for	O
sleep	O
apnea	O
(	O
n	O
=	O
12	O
)	O
.	O

Study	B-Study_Cohort
samples	I-Study_Cohort
were	I-Study_Cohort
obtained	I-Study_Cohort
from	I-Study_Cohort
newly	I-Study_Cohort
diagnosed	I-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
HNSCC	I-Study_Cohort
treated	O
at	O
Louisiana	O
State	O
University	O
Health	O
Science	O
Center	O
,	O
Shreveport	B-Study_Location
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
.	O

Laser	O
capture	O
microdissection	O

Parafﬁn	O
-	O
embedded	O
specimens	B-HPV_Sample_Type
of	O
all	O
tissue	B-HPV_Sample_Type
groups	O
were	O
cut	O
to	O
a	O
thickness	O
of	O
4	O
lm	O
and	O
stained	O
.	O

Epithelial	O
cells	O
were	O
identiﬁed	O
by	O
morphology	O
and	O
captured	O
using	O
LCM	O
(	O
16	O
)	O
.	O

Only	O
cells	O
in	O
the	O
keratogenous	O
zone	O
were	O
captured	O
.	O

Total	O
RNA	O
from	O
captured	O
cells	O
was	O
extracted	O
,	O
puriﬁed	O
,	O
DNase	O
treated	O
,	O
and	O
reverse	O
-	O
transcribed	O
.	O

A	O
human	O
formalin	O
-	O
ﬁxed	O

universal	O
reference	O
RNA	O
was	O
reverse	O
-	O
transcribed	O
in	O
parallel	O
for	O
use	O
as	O
a	O
positive	O
control	O
.	O

Detection	O
of	O
EBV	O
and	O
HPV	O

Epstein–Barr	O
virus	O
status	O
was	O
determined	O
on	O
tissue	B-HPV_Sample_Type
slides	O
by	O
ISH	B-HPV_Lab_Technique
using	I-HPV_Lab_Technique
EBER1	I-HPV_Lab_Technique
DNP	I-HPV_Lab_Technique
Probe	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Ventana	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Tucson	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
AZ	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	O
.	O

Also	O
EBV	O
status	O
was	O
determined	O
in	O
the	O
epithelial	O
cell	O
samples	B-HPV_Sample_Type
captured	O
by	O
LCM	O
via	O
analysis	O
of	O
EBV	O
-	O
encoded	O
RNA1	O
(	O
EBER1	O
)	O
expression	O
using	O
qRT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	O

Tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
were	O
examined	O
for	O
their	O
HPV	O
status	O
using	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
The	I-HPV_Lab_Technique
Delta	I-HPV_Lab_Technique
Pathology	I-HPV_Lab_Technique
Group	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
LLC	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Shreveport	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
LA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	O
and	O
our	O
study	O
pathologist	O
then	O
scored	O
the	O
samples	B-HPV_Sample_Type
as	O
either	O
positive	O
or	O
negative	O
for	O
staining	O
of	O
epithelial	O
cells	O
.	O

The	O
INFORM	O
HPV	O
III	O
Family	O
16	O
(	O
B	O
)	O
probe	O
from	O
Ventana	O
was	O
used	O
to	O
detect	O
HPV	O
genotypes	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
and	O
66	O
.	O

Tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
were	O
also	O
evaluated	O
by	O
immunohistochemistry	B-HPV_Lab_Technique
for	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
as	I-HPV_Lab_Technique
a	I-HPV_Lab_Technique
surrogate	I-HPV_Lab_Technique

marker	I-HPV_Lab_Technique
for	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
related	I-HPV_Lab_Technique
oropharyngeal	I-HPV_Lab_Technique
carcinoma	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
CINtec®	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
Histology	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
Ventana	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

Reverse	B-HPV_Lab_Technique
transcriptase	I-HPV_Lab_Technique
real	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
quantitative	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique

Reverse	B-HPV_Sample_Type
transcriptase	I-HPV_Sample_Type
quantitative	I-HPV_Sample_Type
PCR	I-HPV_Sample_Type
was	O
performed	O
as	O
previously	O
described	O
(	O
16	O
)	O
to	O
detect	O
the	O
presence	O
of	O
the	O
EBV	O
EBER	O
1	O
,	O
CD21	O
,	O
GAPDH	O
,	O
and	O
CD20	O
transcripts	O
.	O

EBER	O
1	O
was	O

30	O
detected	O
with	O
primers	O
50	O
-	O
CGTCCCGGGTACAAGTCC	O
-	O
30	O
and	O
50	O
-	O
AAGACGGCAGAAAGCAGAGTCT	O
-	O
30	O
and	O
the	O
probe	O
50	O
-	O
/	O
56	O
-	O
FAM	O
/	O
TGAGGACGGTGTCTGTGGTTGT	O
CTTCC	O
/	O
36	O
-	O
TAMSp	O
/	O
-	O
30	O
.	O

Primers	O
and	O
probes	O
for	O
CD21	O
,	O
CD20	O
,	O
and	O
GAPDH	O
were	O
as	O
described	O
previously	O
(	O
16	O
)	O
.	O

The	O

level	O
of	O
CD21	O
mRNA	O
expression	O
relative	O
to	O
GAPDH	O
was	O
calculated	O
by	O
the	O
comparative	O
Ct	O
method	O
(	O
17	O
)	O
.	O

CD20	O
was	O
ampliﬁed	O
to	O
control	O
for	O
potential	O
inclusion	O
of	O
EBV	O
-	O
infected	O
B	O
cells	O
.	O

Control	O
experiments	O
showed	O
that	O
the	O
sensitivity	O
of	O
the	O
assay	O
was	O
such	O
that	O
1	O
B	O
cell	O
could	O
be	O
detected	O
in	O
a	O
background	O
of	O
1000	O
epithelial	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

qRT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
to	O
detect	O

HPV16	O
E7	O
was	O
carried	O
out	O
with	O
primers	O
50	O
-	O
ATGA	O
GCAATTAAATGACAGCTCAGAG	O
-	O
30	O
,	O
(	O
nt	O
660	O
-	O
635	O
)	O
and	O

50	O
-	O
CACACTTGCAACAAAAGGTTACAAT	O
-	O
30	O
(	O
nt	O
732–	O

745	O
)	O
,	O
and	O
ampliﬁcation	O
was	O
detected	O
with	O
Power	O
SYBR	O
green	O

(	O
Applied	O
Biosystems	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
speciﬁcity	O
of	O
ampliﬁcations	O
was	O
conﬁrmed	O
by	O
melting	O
curve	O
analysis	O
.	O

Cell	O
lines	O

FaDu	O
,	O
a	O
cancer	O
cell	O
line	O
established	O
from	O
hypopharyngeal	O
SCC	O
,	O
was	O
procured	O
from	O
ATCC	O
.	O

FaDu	O
cultures	O
were	O
maintained	O
in	O
Minimum	O
Essential	O
Medium	O
(	O
MEM	O
)	O
media	O
supplemented	O
with	O
10	O
%	O
FBS	O
and	O
non	O
-	O
essential	O
amino	O
acids	O
.	O

Normal	O
oral	O
keratinocytes	O
(	O
NOK	O
)	O
,	O
a	O
gift	O
from	O
Dr	O
.	O
Carl	O
Munger	O
at	O
Harvard	O
Medical	O
School	O
/	O
Brigham	O
and	O
Women’s	O
Hospital	O
,	O
Boston	O
,	O
MA	O
,	O
USA	B-Study_Location
,	O
were	O
cultured	O
in	O
keratinocyte	O
serum	O
-	O
free	O
medium	O
(	O
KSFM	O
)	O
supplemented	O
with	O
bovine	O
pituitary	O
extract	O
and	O
human	O
epidermal	O
growth	O
factor	O
(	O
hEGF	O
)	O
.	O

The	O
cell	O
clones	O
of	O
FaDu	O
and	O
NOK	O
with	O
four	O
different	O
combinations	O
of	O
EBV	O
/	O
HPV	O
expression	O
were	O
generated	O
(	O
HPV	O
/	O
EBV	O
,	O
HPV	O
/	O
EBV	O
+	O
,	O
HPV	O
+	O
/	O
EBV	O
,	O
and	O
HPV	O
+	O
/	O

EBV	O
+	O
)	O
by	O
stably	O
transfecting	O
the	O
cells	O
with	O
a	O
plasmid	O
carrying	O
HPV16	O
E6	O
and	O
E7	O
ORFs	O
under	O
the	O
control	O
of	O
the	O
immediate	O
early	O
cytomegalovirus	O
promoter	O
in	O
plasmids	O
carrying	O
hygro	O
-	O
mycin	O
resistance	O
(	O
FaDu	O
)	O
or	O
Zeocin	O
(	O
NOK	O
)	O
for	O
selection	O
.	O

Cognate	O
control	O
vector	O
lacking	O
E6	O
and	O
E7	O
was	O
transfected	O
as	O
controls	O
.	O

Then	O
,	O
these	O
cells	O
were	O
infected	O
with	O
a	O
recombinant	O
EBV	O
strain	O
carrying	O
a	O
neomycin	O
resistance	O
cassette	O
or	O
transfected	O
with	O
a	O
vector	O
control	O
carrying	O
the	O
neomycin	O
resistance	O
cassette	O
.	O

EBV	O
positivity	O
and	O
ectopic	O
expression	O
of	O
E6	O
and	O
E7	O
were	O
conﬁrmed	O
using	O
reverse	O
transcription	O
PCR	B-HPV_Lab_Technique

with	O
gene	O
-	O
speciﬁc	O
primers	O
(	O
HPV16	O
E6F	O
–	O
50	O
CTG	O
CAA	O
TGT	O
TTC	O
AGG	O
ACC	O
C	O
30	O
;	O
HPV16	O
E6R	O
–	O
50	O
TCA	O
GGA	O
CAC	O
AGT	O
GGC	O
TTTT	O
30	O
;	O
HPV16	O
E7F	O
–	O
50	O
CCC	O
AGC	O
TGT	O
AAT	O
CAT	O
GCA	O
TG	O
30	O
;	O
HPV16	O
E7R	O
–	O
50	O
TGC	O
CCA	O
TTA	O
ACA	O
GGT	O
CTT	O
CC	O
30	O
;	O
EBV	O
LMP2F	O
–	O
50	O
CGACCCCATATCGCAACACT	O
30	O
;	O
EBV	O
LMP2R	O
–	O
50	O
CGTGCCATTGCTGTGGAAG	O
30	O
)	O
.	O

Cell	O
proliferation	O
assay	O

To	O
determine	O
whether	O
HPV	O
/	O
EBV	O
coinfection	O
enhances	O
cell	O
growth	O
,	O
an	O
in	O
vitro	O
cell	O
proliferation	O
assay	O
was	O
conducted	O
on	O
both	O
FaDu	O
and	O
NOK	O
by	O
either	O
cell	O
counting	O
or	O
using	O
MTS	O
tetrazolium	O
compound	O
/	O
phenazine	O
methosulfate	O
system	O
according	O
to	O
the	O
manufacturer’s	O
instructions	O
(	O
CellTiter	O
96	O
AQueous	O
cell	O
proliferation	O
assay	O
;	O
Promega	O
Corp	O
.	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Each	O
assay	O
was	O
conducted	O
at	O
least	O
three	O
times	O
for	O
statistical	O
signiﬁcance	O
.	O

Cell	O
invasion	O
assay	O

The	O
same	O
four	O
HPV	O
/	O
EBV	O
cell	O
clones	O
of	O
FaDu	O
and	O
NOK	O
were	O
used	O
for	O
cell	O
invasion	O
assay	O
using	O
24	O
-	O
well	O
plates	O
and	O

transwell	O
inserts	O
with	O
an	O
8	O
lm	O
pore	O
size	O
.	O

The	O
interiors	O
of	O
the	O
transwells	O
were	O
collagenized	O
using	O
100	O
ll	O
of	O
15	O
lg	O
/	O
ml	O
collagen	O
solution	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O

Louis	O
,	O
MO	O
,	O
USA	O
from	O
human	O
ﬁbroblasts	O
)	O
and	O
incubated	O
at	O
4°C	O
overnight	O
.	O

The	O
next	O
day	O
,	O
wells	O
in	O
24	O
-	O
well	O
plates	O
were	O
loaded	O
with	O

600	O
ll	O
of	O
serum	O
-	O
free	O
(	O
for	O
FaDu	O
cells	O
)	O
or	O
pituitary	O
extract	O
/	O
EGF	O
-	O
free	O
(	O
for	O
NOK	O
cells	O
)	O
media	O
.	O

In	O
one	O
set	O
of	O
wells	O
,	O
medium	O
with	O
no	O
lysophosphatidic	O
acid	O
(	O
LPA	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
used	O
to	O
evaluate	O
baseline	O
cell	O
invasiveness	O

and	O
compared	O
with	O
LPA	O
-	O
induced	O
invasiveness	O
.	O

Collage	O
-	O
nized	O
transwell	O
inserts	O
were	O
washed	O
and	O
placed	O
into	O
the	O
wells	O
with	O
culture	O
media	O
.	O

Twenty	O
thousand	O
cells	O
were	O
plated	O
per	O
well	O
into	O
each	O
insert	O
and	O
incubated	O
for	O
24	O
h	O
.	O

Then	O
,	O
the	O
inside	O
of	O
each	O
transwell	O
was	O
swabbed	O
to	O
remove	O
any	O
cells	O

that	O
had	O
not	O
migrated	O
through	O
the	O
8	O
-	O
lm	O
pores	O
.	O

Cells	O
were	O
then	O
ﬁxed	O
with	O
methanol	O
and	O
stained	O
with	O
0	O
.	O
2	O
%	O
Crystal	O
Violet	O
.	O

The	O
number	O
of	O
cells	O
that	O
had	O
invaded	O
was	O
determined	O
using	O
light	O
microscopy	O
at	O
9200	O
magniﬁcation	O
.	O

This	O
experiment	O
was	O
repeated	O
six	O
times	O
for	O
statistical	O

signiﬁcance	O
.	O

Statistics	O

Proliferating	O
cell	O
percentages	O
were	O
compared	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Student’s	O
t	O
-	O
test	O
was	O
used	O
to	O
determine	O
signiﬁcant	O
differences	O
between	O
non	O
-	O
cancer	O
and	O
cancer	O
groups	O
for	O
expression	O
of	O
each	O
biomarker	O
.	O

One	O
-	O
way	O
ANOVA	O
was	O
also	O
used	O
to	O
determine	O
signiﬁcant	O
differences	O
in	O
CD21	O
levels	O
and	O
the	O
differences	O
between	O
single	O
and	O
coinfected	O
tissues	B-HPV_Sample_Type
.	O

Tukey’s	O
multiple	O
comparison	O
post	O
hoc	O
test	O
was	O
performed	O
to	O
evaluate	O
differences	O
between	O
groups	O
.	O

Chi	O
-	O
square	O
test	O
of	O
independence	O
was	O
performed	O
to	O
examine	O
the	O
relation	O
between	O
cancer	O
and	O
virus	O
combinations	O
.	O

